Physician profile
Aimee Goedecke
NPI 1972567998
$2,211.06
in general payments reported to CMS, 2019-2025
21 companies · $570 in 2025
The $570 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $113 · 2021: $222 · 2022: $253 · 2023: $459 · 2024: $487 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $439.34 | 2021-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $422.70 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Ironshore Pharmaceuticals INC. | $273.70 | 2019-2024 | Jornay Pm |
| Corium, LLC | $187.25 | 2021-2025 | Azstarys |
| Pfizer INC. | $176.22 | 2019-2025 | |
| Biomarin Pharmaceutical INC. | $103.99 | 2025 | |
| Seqirus USA INC | $87.80 | 2024-2025 | Flucelvax |
| Sanofi Pasteur INC. | $86.50 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $72.54 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $62.03 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $45.78 | 2025 | Xelstrym |
| Merck Sharp & Dohme LLC | $41.76 | 2023-2025 | Gardasil 9, Rotateq, Vaxneuvance |
| Neuraxis, INC. | $37.67 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $33.93 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $33.03 | 2024 | Flumist Quadrivalent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $24.58 | 2022 | |
| Sobi, INC | $23.83 | 2023 | |
| Phadia US INC. | $16.59 | 2025 | Immunocap |
| Takeda Pharmaceuticals U.S.A., INC. | $14.69 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.65 | 2025 | Zoryve |
| Genentech USA, INC. | $13.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Goedecke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.